Grab those receipts, savvy shoppers.
There has been a new development in a string of legal battles for Nurofen manufactures Reckitt Benckiser, with a $3.5 million settlement reached in a consumer class action suit over misleading packaging on products on the Australian market between 2011 and 2015.
Australian’s could be eligible for compensation if they purchased Nurofen in the three year period, with Bannister Law firm confirming the $3.5 million settlement be used to reimburse consumers.
The suit began after the ACCC (Australia’s competition regulator and national consumer law champion) asserted and successfully established that Nurofen products for back pain, period pain, migraines and tension headaches all had exactly the same ingredients, something users have suspected for some time.
This misleading information breaches the country’s consumer law and the ACCC says customers need to be reimbursed.
The reimbursement scheme is before the federal court and the next steps will be released imminently.
A spokesperson from the company said,
“Nurofen Australia apologises to our consumers who may have been misled by the Nurofen Specific Pain Range packaging.”
“Nurofen has offered to settle the Specific Pain Range class action in Australia to ensure that consumers who may have been misled are appropriately and swiftly compensated.”
We will update with more information on the compensation process when it becomes available.
Nurofen fined $6million for misleading consumers in 2016
Early last year, the federal government found Reckitt Benckiser, the company responsible for making and marketing Nurofen, guilty of falsely claiming that some of the brand’s products could treat individual types of pain.
Read more about that here.
